BioCryst Pharmaceuticals
BCRX
BCRX
235 hedge funds and large institutions have $1.08B invested in BioCryst Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 84 increasing their positions, 76 reducing their positions, and 26 closing their positions.
Holders
235
Holders Change
+2
Holders Change %
+0.86%
% of All Funds
3.45%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.07%
New
32
Increased
84
Reduced
76
Closed
26
Calls
$22.1M
Puts
$9.05M
Net Calls
+$13M
Net Calls Change
-$3.56M
Top Buyers
1 |
1
Morgan Stanley
New York
|
$37.6M |
2 |
2
Vanguard Group
Malvern,
Pennsylvania
|
$106M |
3 |
3
State Street
Boston,
Massachusetts
|
$76.5M |
4 |
4
BlackRock
New York
|
$112M |
5 |
5
Balyasny Asset Management
Chicago,
Illinois
|
$11.8M |